198 related articles for article (PubMed ID: 33642497)
1. [Potential Anticancer Activity of Auranofin].
Momose I; Onodera T; Kawada M
Yakugaku Zasshi; 2021; 141(3):315-321. PubMed ID: 33642497
[TBL] [Abstract][Full Text] [Related]
2. Potential Anticancer Activity of Auranofin.
Onodera T; Momose I; Kawada M
Chem Pharm Bull (Tokyo); 2019; 67(3):186-191. PubMed ID: 30827998
[TBL] [Abstract][Full Text] [Related]
3. Sugar-Modified Analogs of Auranofin Are Potent Inhibitors of the Gastric Pathogen
Epstein TD; Wu B; Moulton KD; Yan M; Dube DH
ACS Infect Dis; 2019 Oct; 5(10):1682-1687. PubMed ID: 31487153
[No Abstract] [Full Text] [Related]
4. Repurposing of auranofin: Thioredoxin reductase remains a primary target of the drug.
Zhang X; Selvaraju K; Saei AA; D'Arcy P; Zubarev RA; Arnér ES; Linder S
Biochimie; 2019 Jul; 162():46-54. PubMed ID: 30946948
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of thioredoxin reductase by auranofin induces apoptosis in adriamycin-resistant human K562 chronic myeloid leukemia cells.
Liu JJ; Liu Q; Wei HL; Yi J; Zhao HS; Gao LP
Pharmazie; 2011 Jun; 66(6):440-4. PubMed ID: 21699084
[TBL] [Abstract][Full Text] [Related]
6. Auranofin inactivates Trichomonas vaginalis thioredoxin reductase and is effective against trichomonads in vitro and in vivo.
Hopper M; Yun JF; Zhou B; Le C; Kehoe K; Le R; Hill R; Jongeward G; Debnath A; Zhang L; Miyamoto Y; Eckmann L; Land KM; Wrischnik LA
Int J Antimicrob Agents; 2016 Dec; 48(6):690-694. PubMed ID: 27839893
[TBL] [Abstract][Full Text] [Related]
7. Repurposing of the gold drug auranofin and a review of its derivatives as antibacterial therapeutics.
Liu Y; Lu Y; Xu Z; Ma X; Chen X; Liu W
Drug Discov Today; 2022 Jul; 27(7):1961-1973. PubMed ID: 35192926
[TBL] [Abstract][Full Text] [Related]
8. Auranofin, a thioredoxin reductase inhibitor, causes platelet death through calcium overload.
Harper MT
Platelets; 2019; 30(1):98-104. PubMed ID: 29194002
[TBL] [Abstract][Full Text] [Related]
9. Sublethal concentrations of diverse gold compounds inhibit mammalian cytosolic thioredoxin reductase (TrxR1).
Omata Y; Folan M; Shaw M; Messer RL; Lockwood PE; Hobbs D; Bouillaguet S; Sano H; Lewis JB; Wataha JC
Toxicol In Vitro; 2006 Sep; 20(6):882-90. PubMed ID: 16510263
[TBL] [Abstract][Full Text] [Related]
10. Selective inhibition of endogenous antioxidants with Auranofin causes mitochondrial oxidative stress which can be countered by selenium supplementation.
Radenkovic F; Holland O; Vanderlelie JJ; Perkins AV
Biochem Pharmacol; 2017 Dec; 146():42-52. PubMed ID: 28947276
[TBL] [Abstract][Full Text] [Related]
11. Auranofin, an inhibitor of thioredoxin reductase, induces apoptosis in hepatocellular carcinoma Hep3B cells by generation of reactive oxygen species.
Hwang-Bo H; Jeong JW; Han MH; Park C; Hong SH; Kim GY; Moon SK; Cheong J; Kim WJ; Yoo YH; Choi YH
Gen Physiol Biophys; 2017 Apr; 36(2):117-128. PubMed ID: 28218611
[TBL] [Abstract][Full Text] [Related]
12. Upgrade of an old drug: Auranofin in innovative cancer therapies to overcome drug resistance and to increase drug effectiveness.
Gamberi T; Chiappetta G; Fiaschi T; Modesti A; Sorbi F; Magherini F
Med Res Rev; 2022 May; 42(3):1111-1146. PubMed ID: 34850406
[TBL] [Abstract][Full Text] [Related]
13. Enhancement of auranofin-induced apoptosis in MCF-7 human breast cells by selenocystine, a synergistic inhibitor of thioredoxin reductase.
Liu C; Liu Z; Li M; Li X; Wong YS; Ngai SM; Zheng W; Zhang Y; Chen T
PLoS One; 2013; 8(1):e53945. PubMed ID: 23342042
[TBL] [Abstract][Full Text] [Related]
14. Cross-talk between two antioxidants, thioredoxin reductase and heme oxygenase-1, and therapeutic implications for multiple myeloma.
Raninga PV; Di Trapani G; Vuckovic S; Tonissen KF
Redox Biol; 2016 Aug; 8():175-85. PubMed ID: 26795735
[TBL] [Abstract][Full Text] [Related]
15. Unveiling the Potential of Innovative Gold(I) and Silver(I) Selenourea Complexes as Anticancer Agents Targeting TrxR and Cellular Redox Homeostasis.
De Franco M; Saab M; Porchia M; Marzano C; Nolan SP; Nahra F; Van Hecke K; Gandin V
Chemistry; 2022 Dec; 28(70):e202201898. PubMed ID: 36106679
[TBL] [Abstract][Full Text] [Related]
16. Metal- and Semimetal-Containing Inhibitors of Thioredoxin Reductase as Anticancer Agents.
Gandin V; Fernandes AP
Molecules; 2015 Jul; 20(7):12732-56. PubMed ID: 26184149
[TBL] [Abstract][Full Text] [Related]
17. Noble metal targeting of thioredoxin reductase--covalent complexes with thioredoxin and thioredoxin-related protein of 14 kDa triggered by cisplatin.
Prast-Nielsen S; Cebula M; Pader I; Arnér ES
Free Radic Biol Med; 2010 Dec; 49(11):1765-78. PubMed ID: 20851179
[TBL] [Abstract][Full Text] [Related]
18. Transcriptional changes of proteins of the thioredoxin and glutathione systems in Acanthamoeba spp. under oxidative stress - an RNA approach.
Köhsler M; Leitsch D; Loufouma Mbouaka A; Wekerle M; Walochnik J
Parasite; 2022; 29():24. PubMed ID: 35532265
[TBL] [Abstract][Full Text] [Related]
19. Auranofin radiosensitizes tumor cells through targeting thioredoxin reductase and resulting overproduction of reactive oxygen species.
Wang H; Bouzakoura S; de Mey S; Jiang H; Law K; Dufait I; Corbet C; Verovski V; Gevaert T; Feron O; Van den Berge D; Storme G; De Ridder M
Oncotarget; 2017 May; 8(22):35728-35742. PubMed ID: 28415723
[TBL] [Abstract][Full Text] [Related]
20. Structure-activity relationships in a series of auranofin analogues showing remarkable antiproliferative properties.
Landini I; Massai L; Cirri D; Gamberi T; Paoli P; Messori L; Mini E; Nobili S
J Inorg Biochem; 2020 Jul; 208():111079. PubMed ID: 32497830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
